The Covid-19 pandemic is shaking up well-established business models and dispelling long-held assumptions, holding out an opportunity to reshape and democratise healthcare around the planet.
The future will call for a new approach to prevention, screening, diagnosis, therapy, monitoring and management of diseases. We are likely to see convergence of translational research in biomedicine with disciplines such as public health, epidemiology, infectious disease modelling and data science. The multidisciplinary approach will demand a reimagining of biomedical innovation.
The availability of genetic information, together with other phenotypic as well as medical information, is helping identify new drug targets by linking particular genes and their products to individual diseases. In addition to genomic data, other data have also moved into the spotlight. Proteomics and metabolomics, as well as epigenetics and an integrated view of all of these disciplines, are gaining traction. Also, the impact of lifestyle choices is starting to be factored in.
On the other end of the spectrum, electronic health records and other patient-related information in registries and hospital administration databases are helping establish real-world evidence for effectiveness of a particular medicine.
Researchers today are relying on multiplexed data sets to make drug discovery and development more innovative, cheaper and faster.
Data Science For Affordable Innovation
Drug discovery is capital intensive, research-intensive and intellectual property-intensive with inherently long time lines.
This story is from the August 23, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the August 23, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Leapfrogging Into The Future
Gen AI is the future. In India, this revolutionary technology has already penetrated deep into the country's banking sector
The Visionary
In a career spanning nearly four decades, Uday Kotak, a firstgeneration entrepreneur, has not only created a bank of size but also built an institution, which offers a wide range of financial services, from asset management and insurance to securities
Is The Tie Dead?
Maybe not. But it is no longer de facto office wear and is slowly being reduced to something to be worn only on special occasions
"Bring in experts to understand customers"
Qualcomm-backed ideaForge Technology is a Mumbai-based drone manufacturer
SHAKING IT UP
AMERICAN PHARMA MAJOR ELI LILLY SEES INDIA AS ITS LAUNCHPAD FOR A NEW GROWTH TRAJECTORY, USING ITS NEW DRUGS FOR DIABETES AND OBESITY AS THE FUEL. WILL THIS STRATEGIC PIVOT WORK?
"Besides China, no one can match the scale that India offers"
Romal Shetty, CEO of Deloitte South Asia, says innovations coming out of India are being replicated globally, and the country holds great strategic value for the Big 4 firm
PICKING THE WINNERS
The methodology used for the Business Today-KPMG Best Banks and NBFCs Survey 2022-23
THE SMALL FIRM'S BEST FRIEND
Lendingkart, a fintech that posted its highest-ever PAT in FY23, is making credit available to MSMEs in India's far-flung areas
HELPING HAND
From helping financial institutions with e-verifications to aiding them in fraud detection and prevention, Perfios is bridging the gap between data and insights
THE OMNIPRESENT PLATFORM
Fintech major Razorpay has undergone many diversifications. Yet, its core premise remains the same: make the movement of money simpler